Date published: 2026-4-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

CSS2 Activators

The chemical class known as "AT-rich interaction domain 1A Activators," if it were defined, would refer to a group of compounds that selectively enhance the expression or activity of the AT-rich interaction domain 1A (ARID1A) protein, which is a component of the SWI/SNF chromatin remodeling complex. These activators would likely function by interacting with the regulatory regions of the ARID1A gene or by modulating the protein's activity directly. The specific chemical structures of these activators could vary greatly, with each molecule having unique properties that allow for the preferential targeting of ARID1A. The activation process might involve increased transcription of the ARID1A gene, stabilization of its mRNA, enhanced translation, or prevention of protein degradation. Alternatively, it could involve direct binding to the ARID1A protein, inducing a conformational change that leads to its activation. Given the role of ARID1A in chromatin remodeling, compounds that modulate its activity would be critical tools for studying gene expression and chromatin dynamics.

From a biochemical perspective, this class of compounds would require thorough characterization to understand how they influence ARID1A. Studies would involve dissecting the molecular pathways leading to the upregulation of ARID1A expression or activity. This could entail the use of advanced analytical techniques to observe the interaction between the activators and the ARID1A protein or its gene promoter. Understanding how these compounds affect ARID1A function would involve detailed kinetic analyses, binding studies, and perhaps structural biology approaches such as crystallography or NMR spectroscopy to visualize how these molecules interact at the atomic level. The development of ARID1A activators would provide insight into the mechanics of chromatin remodeling and expand our knowledge of gene regulation within the complex landscape of the cell nucleus.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

5-Aza-2′-Deoxycytidine

2353-33-5sc-202424
sc-202424A
sc-202424B
25 mg
100 mg
250 mg
$218.00
$322.00
$426.00
7
(1)

This compound may inhibit DNA methyltransferases, potentially demethylating the ARID1A promoter and upregulating expression.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$152.00
$479.00
$632.00
$1223.00
$2132.00
33
(3)

As a histone deacetylase inhibitor, it might increase histone acetylation and thus promote ARID1A expression.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$133.00
$275.00
37
(2)

Another histone deacetylase inhibitor that could enhance the transcription of genes including ARID1A.

Panobinostat

404950-80-7sc-208148
10 mg
$200.00
9
(1)

This broad-spectrum histone deacetylase inhibitor may also upregulate ARID1A expression through epigenetic changes.

Valproic Acid

99-66-1sc-213144
10 g
$87.00
9
(1)

By inhibiting histone deacetylase, valproic acid can activate silent genes, possibly affecting ARID1A.

RG 108

48208-26-0sc-204235
sc-204235A
10 mg
50 mg
$131.00
$515.00
2
(1)

RG108 is a DNA methyltransferase inhibitor that might induce ARID1A by reducing methylation at its promoter.

Mithramycin A

18378-89-7sc-200909
1 mg
$55.00
6
(1)

It binds to GC-rich DNA sequences, possibly affecting transcription factors that regulate ARID1A expression.

Disulfiram

97-77-8sc-205654
sc-205654A
50 g
100 g
$53.00
$89.00
7
(1)

Disulfiram can modulate various molecular pathways and might indirectly upregulate ARID1A.

6-Thioguanine

154-42-7sc-205587
sc-205587A
250 mg
500 mg
$42.00
$54.00
3
(1)

This compound serves as a histone deacetylase inhibitor and could increase ARID1A expression.

D,L-Sulforaphane

4478-93-7sc-207495A
sc-207495B
sc-207495C
sc-207495
sc-207495E
sc-207495D
5 mg
10 mg
25 mg
1 g
10 g
250 mg
$153.00
$292.00
$489.00
$1325.00
$8465.00
$933.00
22
(1)

Sulforaphane is known to affect epigenetic status and gene expression, potentially impacting ARID1A levels.